Practical approach to vasculitides in adults: an overview of clinical conditions that can mimic vasculitides closely

Abstract

Primary systemic vasculitides are rare diseases affecting blood vessel walls. The type and patterns of distribution of the organs affected usually reflect the size of the vessels predominantly involved, and the patterns of clinical manifestations are generally useful to reach a specific diagnosis. However, presenting symptoms may lack adequate specificity for a prompt diagnosis, leading to a diagnostic (and therapeutic) delay, often causing irreversible damage to the affected organs. Due to their rarity and variable clinical presentation, the diagnosis of primary vasculitides could be challenging for physicians. Vasculitis mimickers, i.e. the clinical conditions that could be likely mistaken for vasculitides, need to be carefully ruled out, especially before starting the immunosuppressive therapy. We present here a practical approach to the diagnosis of primary systemic vasculitides involving large, medium and small size vessels, and reviewed most of the conditions that could mimic primary systemic vasculitides.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

References

Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med. 1997;337(21):1512–23.

Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37(2):187–92.

Hoffman GS, Calabrese LH. Vasculitis: determinants of disease patterns. Nat Rev Rheumatol. 2014;10(8):454–62.

Takala JH, Kautiainen H, Malmberg H, Leirisalo-Repo M. Incidence of Wegener’s granulomatosis in Finland 1981-2000. Clin Exp Rheumatol. 2008;26(3 Suppl 49):S81-5.

Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, Martinez-Taboada VM, Delgado-Rodriguez M, Figueroa M, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 1998;41(8):1497–504.

Basu N, Watts R, Bajema I, Baslund B, Bley T, Boers M, et al. EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis. 2010;69(10):1744–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20448283

Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583–94.

Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009;68(3):318–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18413441

Miloslavsky EM, Lu N, Unizony S, Choi HK, Merkel PA, Seo P, et al. Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener’s): Distinct Patient Subsets. Arthritis Rheumatol. 2016;68(12):2945–52.

Carlson JA, Chen KR. Cutaneous pseudovasculitis. American Journal of Dermatopathology. 2007.

Lie JT. Vasculitis look-alikes and pseudovasculitis syndromes. Curr Diagnostic Pathol. 1995;

Miloslavsky EM, Stone JH, Unizony SH. Challenging mimickers of primary systemic vasculitis. Rheumatic Disease Clinics of North America. 2015.

Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66(2):222–7.

Watts RA, Lane SE, Scott DG, Koldingsnes W, Nossent H, Gonzalez-Gay MA, et al. Epidemiology of vasculitis in Europe. Ann Rheum Dis. 2001;60(12):1156–7.

Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11.

Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33(8):1094–100.

Lightfoot RW, Michel BA, Bloch DA, Hunder GG, Zvaifler NJ, McShane DJ, et al. The American college of rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum. 1990;

Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122–8.

Watts R a, Scott DG. Classification and epidemiology of the vasculitides. Baillieres Clin Rheumatol. 1997;11(2):191–217. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14997613

Hočevar A, Rotar Z, Jurčić V, Pižem J, Čučnik S, Vizjak A, et al. IgA vasculitis in adults: The performance of the EULAR/PRINTO/PRES classification criteria in adults. Arthritis Res Ther. 2016;

Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11.

Craven A, Robson J, Ponte C, Grayson PC, Suppiah R, Judge A, et al. ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). Clin Exp Nephrol. 2013;17(5):619–21.

Gibelin A, Maldini C, Mahr A. Epidemiology and etiology of wegener granulomatosis, microscopic polyangiitis, churg-strauss syndrome and goodpasture syndrome: vasculitides with frequent lung involvement. Semin Respir Crit Care Med. 2011;32(3):264–73.

Felicetti M, Cazzador D, Padoan R, Pendolino AL, Faccioli C, Nardello E, et al. Ear, nose and throat involvement in granulomatosis with polyangiitis: how it presents and how it determines disease severity and long-term outcomes. Clin Rheumatol. 2018;37(4):1075–83.

Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951;27(2):277–301.

Groh M, Pagnoux C, Baldini C, Bel E, Bottero P, Cottin V, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 2015;26(7):545–53.

Nishino H, Rubino FA, DeRemee RA, Swanson JW, Parisi JE. Neurological involvement in Wegener’s granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol. 1993;33(1):4–9.

Sassi S Ben, Ghorbel I Ben, Mizouni H, Houman MH, Hentati F. Microscopic polyangiitis presenting with peripheral and central neurological manifestations. Neurol Sci. 2011;32(4):727–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21681367

Hattori N, Mori K, Misu K, Koike H, Ichimura M, Sobue G. Mortality and morbidity in peripheral neuropathy associated Churg-Strauss syndrome and microscopic polyangiitis. J Rheumatol. 2002;29(7):1408–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12136898

Collins MP. The vasculitic neuropathies: An update. Current Opinion in Neurology. 2012 Oct;25(5):573-85.

Dejaco C, Duftner C, Dasgupta B, Matteson EL, Schirmer M. Polymyalgia rheumatica and giant cell arteritis: management of two diseases of the elderly. Aging health. 2011;7(4):633–45. Available from: https://www.futuremedicine.com/doi/abs/10.2217/ahe.11.50

Berti A, Campochiaro C, Cavalli G, Pepe G, Praderio L, Sabbadini MG, et al. Giant cell arteritis restricted to the limb arteries: An overlooked clinical entity. Autoimmun Rev. 2015;14(4):352–7.

Ninet JP, Bachet P, Dumontet CM, Du Colombier PB, Stewart MD, Pasquier JH. Subclavian and axillary involvement in temporal arteritis and polymyalgia rheumatica. Am J Med. 1990;88(1):13–20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2294760

Comarmond C, Biard L, Lambert M, Mekinian A, Ferfar Y, Kahn JE, et al. Long-Term Outcomes and Prognostic Factors of Complications in Takayasu Arteritis: A Multicenter Study of 318 Patients. Circulation. 2017;136(12):1114–22.

Kermani TA, Crowson CS, Muratore F, Schmidt J, Matteson EL, Warrington KJ. Extra-cranial giant cell arteritis and Takayasu arteritis: How similar are they? Semin Arthritis Rheum. 2015;44(6):724–8.

Kermani TA, Warrington KJ, Crowson CS, Ytterberg SR, Hunder GG, Gabriel SE, et al. Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis. 2013;72(12):1989–94.

Berti A, Caporali R, Montecucco C, Paolazzi G, Monti S. Aging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and Management. Drugs Aging. 2019 Jan;36(1):53-63. doi: 10.1007/s40266-018-0617-4.

Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2018;77(6):808-818.

Chen M, Kallenberg CGM. ANCA-associated vasculitides--advances in pathogenesis and treatment. Nat Rev Rheumatol . 2010;6(11):653–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20924413

Cartin-Ceba R, Diaz-Caballero L, Al-Qadi MO, Tryfon S, Fervenza FC, Ytterberg SR, et al. Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes. Arthritis Rheumatol. 2016;68(6):1467–76.

Frumholtz L, Laurent-Roussel S, Aumaitre O, Maurier F, Le Guenno G, Carlotti A, et al. Clinical and pathological significance of cutaneous manifestations in ANCA-associated vasculitides. Autoimmun Rev. 2017;16(11):1138–46.

Kluger N, Pagnoux C, Guillevin L, Francès C. Comparison of cutaneous manifestations in systemic polyarteritis nodosa and microscopic polyangiitis. Br J Dermatol. 2008 Sep;159(3):615-20.

Morgan AJ, Schwartz RA. Cutaneous polyarteritis nodosa: A comprehensive review. Int J Dermatol. 2010 Jul;49(7):750-6. doi: 10.1111/j.1365-4632.2010.04522.x.

Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006; 29;368(9533):404–18. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16876669

Vaglio A, Buzio C, Zwerina J. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art. Allergy. 2013;68(3):261–73.

Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D. Cryoglobulinemia Vasculitis. Am J Med. 2015;128(9):950-5. doi: 10.1016/j.amjmed.2015.02.017.

Lamprecht P, Gause A, Gross WL. Cryoglobulinemic vasculitis. Arthritis and Rheumatism. 1999. doi: https://doi.org/10.1002/1529-0131(199912)42:12<2507::AID-ANR2>3.0.CO;2-%23

Duftner C, Dejaco C, Schirmer M. Polymyalgia rheumatica. Internist (Berl) . 2009;50(1):51–60. Available from: https://doi.org/10.1007/s00108-008-2274-x

Blockmans D, De Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatol. 2007;46(4):672–7.

Alessandra Soriano, Francesco Muratore, Nicolò Pipitone, Luigi Boiardi, Luca Cimino, Carlo Salvarani. Visual loss and other cranial ischaemic complications in giant cell arteritis. Nat Rev Rheumatol. 2017 Aug;13(8):476-484. doi: 10.1038/nrrheum.2017.98

Moura C, Aquino MA, Filho JR, Santiago M. Takayasu’s or tuberculous arteritis? BMJ Case Rep. 2015; 23;2015:bcr2014208717.

Al-Shammari NF, El-Beltagi AH, Al-Far SA, Abdel-Raouf YM. Syphilitic arteritis involving the origin of the cervical internal carotid artery. Neurosciences (Riyadh). 2010 Apr;15(2):122-5.

Katabathina VS, Restrepo CS. Infectious and Noninfectious Aortitis: Cross-Sectional Imaging Findings. Semin Ultrasound CT MR. 2012 Jun;33(3):207-21. doi: 10.1053/j.sult.2011.12.001.

Gonzalez-Gay MA, Pineiro A, Gomez-Gigirey A, Garcia-Porrua C, Pego-Reigosa R, Dierssen-Sotos T, et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore). 2004 Nov;83(6):342-347. doi: 10.1097/01.md.0000145369.25558.b5

Ardies CM, Roberts CK. Atherosclerosis. In: Diet, Exercise, and Chronic Disease: The Biological Basis of Prevention. 2014.

Blockmans D, de Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum. 2006;55(1):131–7.

Koster MJ, Matteson EL, Warrington KJ. Large-vessel giant cell arteritis: Diagnosis, monitoring and management. Rheumatology (United Kingdom). 2018.

Alie N, Eldib M, Fayad ZA, Mani V. Inflammation, atherosclerosis, and coronary artery disease: PET/CT for the evaluation of atherosclerosis and inflammation. Clinical Medicine Insights: Cardiology. 2014.

Tarkin JM, Joshi FR, Rudd JHF. PET imaging of inflammation in atherosclerosis. Nature Reviews Cardiology. 2014.

Mohammad AJ, Englund M, Turesson C, Tomasson G, Merkel PA. Rate of Comorbidities in Giant Cell Arteritis: A Population-based Study. J Rheumatol. 2017;44(1):84–90.

Alibaz-Oner F, Koster MJ, Unal AU, Yildirim HG, Cikikci C, Schmidt J, et al. Assessment of the frequency of cardiovascular risk factors in patients with Takayasu’s arteritis. Rheumatol. 2017;56(11):1939–44.

Kermani TA, Schmidt J, Crowson CS, Ytterberg SR, Hunder GG, Matteson EL, et al. Utility of Erythrocyte Sedimentation Rate and C-Reactive Protein for the Diagnosis of Giant Cell Arteritis. Semin Arthritis Rheum. 2012 Jun;41(6):866-71. doi: 10.1016/j.semarthrit.2011.10.005.

Pipitone N, Versari A, Salvarani C. Role of imaging studies in the diagnosis and follow-up of large-vessel vasculitis: An update. Rheumatology (Oxford). 2008 Apr;47(4):403-8. doi: 10.1093/rheumatology/kem379.

Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 2014;124(4):483-92. doi: 10.1182/blood-2014-03-561381.

Berti A, Ferrarini M, Ferrero E, Dagna L. Cardiovascular manifestations of Erdheim-Chester disease. Clin Exp Rheumatol. 2015;33(2 Suppl 89):S-155-63.

Vaglio A. Chronic periaortitis : a large-vessel vasculitis ? Curr Opin Rheumatol. 2011;23(1):1-6. doi: 10.1097/BOR.0b013e328341137d

Serratrice J, Granel B, De Roux C, Pellissier JF, Swiader L, Bartoli JM, et al. “Coated aorta”: a new sign of Erdheim-Chester disease. J Rheumatol. 2000;27(6):1550–3.

Steňová E, Steňo B, Povinec P, Ondriaš F, Rampalová J. FDG-PET in the Erdheim-Chester disease: its diagnostic and follow-up role. Rheumatol Int. 2012;32(3):675–8.

Haroche J, Cluzel P, Toledano D, Montalescot G, Touitou D, Grenier PA, et al. Images in cardiovascular medicine. Cardiac involvement in Erdheim-Chester disease: magnetic resonance and computed tomographic scan imaging in a monocentric series of 37 patients. Circulation. 2009 ;119(25):e597-8.

Isobe M. Takayasu arteritis revisited : Current diagnosis and treatment. Int J Cardiol. 2013;168(1):3–10. Available from: http://dx.doi.org/10.1016/j.ijcard.2013.01.022

Cavalli G, Guglielmi B, Berti A, Campochiaro C, Sabbadini MG, Dagna L. The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis. 2013;72(10):1691–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23396641

Vaglio A, Buzio C. Chronic periaortitis : a spectrum of diseases. Curr Opin Rheumatol. 2005 Jan;17(1):34-40.

Mouthon L. L45. Aortitis, retroperitoneal fibrosis, and IgG4-related disease. Presse Med. 2013 Apr;42(4 Pt 2):622-5. doi: 10.1016/j.lpm.2013.01.042.

Campochiaro C, Ramirez GA, Bozzolo EP, Lanzillotta M, Berti A, Baldissera E, et al. IgG4-related disease in Italy: Clinical features and outcomes of a large cohort of patients. Scand J Rheumatol. 2016;45(2):135-45. doi: 10.3109/03009742.2015.1055796.

Berti A, Della-Torre E, Gallivanone F, Canevari C, Milani R, Lanzillotta M, et al. Quantitative measurement of 18F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease. Rheumatology (Oxford). 2017 Dec 1;56(12):2084-2092.

Papathanasiou ND, Du Y, Menezes LJ, Almuhaideb A, Shastry M, Beynon H, et al. 18F-Fludeoxyglucose PET/CT in the evaluation of large-vessel vasculitis: diagnostic performance and correlation with clinical and laboratory parameters. Br J Radiol. 2012 Jun;85(1014):e188-94. doi: 10.1259/bjr/16422950.

Soussan M, Nicolas P, Schramm C, Katsahian S, Pop G, Fain O, et al. Management of large-vessel vasculitis with FDG-PET. Medicine (Baltimore). 2015 Apr;94(14):e622. doi: 10.1097/MD.0000000000000622.

Fatima J, Gota C, Clair DG, Billings SD, Gornik HL, Fibrosis R. Inflammatory Abdominal Aortic Aneurysm With Retroperitoneal Fibrosis. Circulation 2014;1300–2.

Della Torre E. IgG4-related disease. In: Systemic Vasculitides: Current Status and Perspectives. 2016.

Lanzillotta M, Campochiaro C, Trimarchi M, Arrigoni G, Gerevini S, Milani R, et al. Deconstructing IgG4-related disease involvement of midline structures: Comparison to common mimickers. Mod Rheumatol. 2017 Jul;27(4):638-645. doi: 10.1080/14397595.2016.1227026.

Deshpande V, Zen Y, Chan JKC, Yi EE, Sato Y, Yoshino T, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012 Sep;25(9):1181-92. doi: 10.1038/modpathol.2012.72.

Khoury MH, Gornik HL. Fibromuscular dysplasia (FMD). Vasc Med (United Kingdom). 2017;

Olin JW, Froehlich J, Gu X, Michael Bacharach J, Eagle K, Gray BH, et al. The United States registry for fibromuscular dysplasia: Results in the first 447 patients. Circulation. 2012 Jun 26;125(25):3182-90.

Olin JW, Sealove BA. Diagnosis, management, and future developments of fibromuscular dysplasia. J Vasc Surg

. 2011 Mar;53(3):826-36.e1. doi: 10.1016/j.jvs.2010.10.066.

Touzé E, Oppenheim C, Trystram D, Nokam G, Pasquini M, Alamowitch S, et al. Fibromuscular dysplasia of cervical and intracranial arteries. Int J Stroke. 2010 Aug;5(4):296-305. doi: 10.1111/j.1747-4949.2010.00445.x.

Persu A, Giavarini A, Touzé E, Januszewicz A, Sapoval M, Azizi M, et al. European consensus on the diagnosis and management of fibromuscular dysplasia. J Hypertens. 2014 Jul;32(7):1367-78. doi: 10.1097/HJH.0000000000000213.

Ahmad A, Oparil S. Hypertension in women. In: Gender Differences in the Pathogenesis and Management of Heart Disease. 2018.

Saw J, Aymong E, Sedlak T, Buller CE, Starovoytov A, Ricci D, et al. Spontaneous coronary artery dissection association with predisposing arteriopathies and precipitating stressors and cardiovascular outcomes. Circ Cardiovasc Interv. 2014 Oct;7(5):645-55. doi: 10.1161/CIRCINTERVENTIONS.114.001760.

Shenouda M, Riga C, Naji Y, Renton S. Segmental arterial mediolysis: A systematic review of 85 cases. Ann Vasc Surg. 2014 Jan;28(1):269-77. doi: 10.1016/j.avsg.2013.03.003.

Kalva SP, Somarouthu B, Jaff MR, Wicky S. Segmental arterial mediolysis: Clinical and imaging features at presentation and during follow-up. J Vasc Interv Radiol. 2011 Oct;22(10):1380-7. doi: 10.1016/j.jvir.2011.07.001.

Baker-LePain JC, Stone DH, Mattis AN, Nakamura MC, Fye KH. Clinical diagnosis of segmental arterial mediolysis: Differentiation from vasculitis and other mimics. Arthritis Care Res (Hoboken). 2010;

Michael M, Widmer U, Wildermuth S, Barghorn A, Duewell S, Pfammatter T. Segmental arterial mediolysis: CTA findings at presentation and follow-up. AJR Am J Roentgenol. 2006 Dec;187(6):1463-9. doi: 10.2214/AJR.05.0281.

Slavin RE. Segmental arterial mediolysis: course, sequelae, prognosis, and pathologic-radiologic correlation. Cardiovasc Pathol. 2009;18(6):352-60. doi: 10.1016/j.carpath.2008.09.001.

Tameo MN, Dougherty MJ, Calligaro KD. Spontaneous dissection with rupture of the superior mesenteric artery from segmental arterial mediolysis. J Vasc Surg. 2011;

Alturkustani M, Ang LC. Intracranial segmental arterial mediolysis: Report of 2 cases and review of the literature. American Journal of Forensic Medicine and Pathology. 2013.

Olin JW. Thromboangiitis obliterans: 110 years old and little progress made. Journal of the American Heart Association. 2018.

Olin JW, Shih A. Thromboangiitis obliterans (Buergerʼs disease). Curr Opin Rheumatol. 2006;

Wu W. N o n a r t e r i o s c l e ro t i c Va s c u l a r Disease. 2013;93:833–75.

Małecki R, Zdrojowy K, Adamiec R. Thromboangiitis obliterans in the 21st century-A new face of disease. Atherosclerosis. 2009.

Puéchal X, Fiessinger JN. Thromboangiitis obliterans or Buerger’s disease: Challenges for the rheumatologist. Rheumatology. 2007.

Vijayakumar A, Tiwari R, Kumar Prabhuswamy V. Thromboangiitis obliterans (Buerger’s Disease) - Current practices. International Journal of Inflammation. 2013.

Seebald J, Gritters L. Thromboangiitis obliterans (Buerger disease). Radiol Case Reports. 2015;

Berti A, Campochiaro C. Painful fingers. Eur J Intern Med. 2013;

Szuba A, Cooke JP. Thromboangiitis obliterans - An update on Buerger’s disease. West J Med. 1998;

Cacione DG, Baptista-Silva JCC, Macedo CR. Pharmacological treatment for Buerger’s disease. Cochrane Database of Systematic Reviews. 2016.

Watts RA, Scott DG. ANCA vasculitis: to lump or split? Why we should study MPA and GPA separately. Rheumatol. 2012/08/28. 2012;51(12):2115–7.

Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;

Bertsias G, Ioannidis JPA, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008;

Francès C, Niang S, Laffitte E, Le Pelletier F, Costedoat N, Piette JC. Dermatologic manifestations of the antiphospholipid syndrome: Two hundred consecutive cases. Arthritis Rheum. 2005;

R. C, G. E. Unusual manifestations of the antiphospholipid syndrome. Int J Clin Rheumtol. 2009;

Espinosa G, Cervera R. Cardiac and Pulmonary Manifestations in the Antiphospholipid Syndrome. Curr Rheumatol Rev. 2010;

R.A. A, R. C. Microvascular and microangiopathic antiphospholipid-associated syndromes (“MAPS”). Semantic or antisemantic? Autoimmun Rev. 2008;

Fleetwood T, Cantello R, Comi C. Antiphospholipid syndrome and the neurologist: From pathogenesis to therapy. Frontiers in Neurology. 2018.

Clark KEN, Giles I. Antiphospholipid syndrome. Medicine (United Kingdom). 2018.

Sciascia S, Cuadrado MJ, Khamashta M, Roccatello D. Renal involvement in antiphospholipid syndrome. Nature Reviews Nephrology. 2014.

Sinico RA, Cavazzana I, Nuzzo M, Vianelli M, Napodano P, Scaini P, et al. Renal involvement in primary antiphospholipid syndrome: Retrospective analysis of 160 patients. Clin J Am Soc Nephrol. 2010;

Berti A, Cornec D, Crowson CS, Specks U, Matteson EL. The epidemiology of ANCA associated vasculitis in Olmsted County, Minnesota (USA): a 20 year population-based study. Arthritis Rheumatol. 2017/09/08. 2017;

Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, De Ramón E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015;

Krause ML, Cartin-Ceba R, Specks U, Peikert T. Update on diffuse alveolar hemorrhage and pulmonary vasculitis. Immunol Allergy Clin North Am. 2012/10/30. 2012;32(4):587–600.

Pennington M, Yeager J, Skelton H, Smith KJ. Cholesterol embolization syndrome: Cutaneous histopathological features and the variable onset of symptoms in patients with different risk factors. Br J Dermatol. 2002;

Saric M, Kronzon I. Aortic atherosclerosis and embolic events. Curr Cardiol Rep. 2012;

Hitti WA, Wali RK, Weinman EJ, Drachenberg C, Briglia A. Cholesterol embolization syndrome induced by thrombolytic therapy. American Journal of Cardiovascular Drugs. 2008.

KLAR JL, TAIRA JW. CHOLESTEROL EMBOLI SYNDROME. Int J Dermatol. 1993;

Saric M, Kronzon I. Cholesterol embolization syndrome. Current Opinion in Cardiology. 2011.

Quinones A, Saric M. The cholesterol emboli syndrome in atherosclerosis. Current atherosclerosis reports. 2013.

Ying CM, Yao DT, Ding HH, Yang C De. Infective endocarditis with antineutrophil cytoplasmic antibody: Report of 13 cases and literature review. PLoS One. 2014;

Mahr A, Batteux F, Tubiana S, Goulvestre C, Wolff M, Papo T, et al. Brief report: Prevalence of antineutrophil cytoplasmic antibodies in infective endocarditis. Arthritis Rheumatol. 2014;

Choi HK, Lamprecht P, Niles JL, Gross WL, Merkel PA. Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthritis Rheum. 2000;

Ghosh GC, Sharma B, Katageri B, Bhardwaj M. ANCA positivity in a patient with infective endocarditis-associated glomerulonephritis: A diagnostic dilemma. Yale J Biol Med. 2014;

Ardalan MR, Trillini M. Infective endocarditis mimics ANCA associated glomerulonephritis. Casp J Intern Med. 2012;

Langlois V, Lesourd A, Girszyn N, Menard JF, Levesque H, Caron F, et al. Antineutrophil cytoplasmic antibodies associated with infective endocarditis. Med (United States). 2016;

Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, Weller PF, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;

Tefferi A, Gotlib J, Pardanani A. Hypereosinophilic syndrome and clonal eosinophilia: Point-of-care diagnostic algorithm and treatment update. Mayo Clinic Proceedings. 2010.

Brito-Babapulle F. The eosinophilias, including the idiopathic hypereosinophilic syndrome. British Journal of Haematology. 2003.

Simon HU, Rothenberg ME, Bochner BS, Weller PF, Wardlaw AJ, Wechsler ME, et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol. 2010;

Cottin V, Bel E, Bottero P, Dalhoff K, Humbert M, Lazor R, et al. Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d’Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on e. Autoimmun Rev. 2016/10/28. 2017;16(1):1–9.

Lin DA, Boyce JA, Sheffer AL. The Idiopathic Hypereosinophilic Syndrome. In: Allergy and Asthma Proceedings. 2003.

Klion A. Hypereosinophilic Syndrome: Current Approach to Diagnosis and Treatment. Annu Rev Med. 2009;

Cottin V, Bel E, Bottero P, Dalhoff K, Humbert M, Lazor R, et al. Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Eur Respir J. 2016/11/02. 2016;48(5):1429–41.

Berti A, Volcheck GW, Cornec D, Smyth RJ, Specks U, Keogh KA. Severe/uncontrolled asthma and overall survival in atopic patients with eosinophilic granulomatosis with polyangiitis. Respir Med [Internet]. 2018;142:66–72. Available from: https://doi.org/10.1016/j.rmed.2018.07.017

Leurs A, Chenivesse C, Lopez B, Gibier J-B, Clément G, Groh M, et al. C-Reactive protein as a diagnostic tool in differential diagnosis of hypereosinophilic syndrome and antineutrophil cytoplasmic antibody–negative eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract . 2019;7(4):1347-1351.e3. Available from: https://www.jaci-inpractice.org/article/S2213-2198(18)30659-7/abstract#.XTDTATyYZjo.mendeley

Published
2020-04-03
Info
Issue
Section
Reviews
Keywords:
Mimicker, vasculitis, ANCA-associated vasculitis, giant cell arteritis, IgG4-related disease, segmental arterial mediolysis, fibromuscular dysplasia, antiphospholipid syndrome.
Statistics
  • Abstract views: 1135

  • PDF: 410
  • HTML: 0
How to Cite
Berti, A., Bond, M., Volpe, A., Felicetti, M., Bortolotti, R., & Paolazzi, G. (2020). Practical approach to vasculitides in adults: an overview of clinical conditions that can mimic vasculitides closely. Beyond Rheumatology, 2(1), 3-13. https://doi.org/10.4081/br.2020.20